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AbstrACt
Introduction Chronic subdural haematomas (CSDHs) are 
one of the most common neurosurgical conditions. The 
goal of surgery is to alleviate symptoms and minimise 
the risk of symptomatic recurrences. In the past, 
reoperation rates as high as 20%–30% were described 
for CSDH recurrences. However, following the introduction 
of subdural drainage, reoperation rates dropped to 
approximately 10%. The standard surgical technique 
includes burr- hole craniostomy, followed by intraoperative 
irrigation and placement of subdural drainage. Yet, the 
role of intraoperative irrigation has not been established. 
If there is no difference in recurrence rates between 
intraoperative irrigation and no irrigation, CSDH surgery 
could be carried out faster and more safely by omitting the 
step of irrigation. The aim of this multicentre randomised 
controlled trial is to study whether no intraoperative 
irrigation and subdural drainage results in non- inferior 
outcome compared with intraoperative irrigation and 
subdural drainage following burr- hole craniostomy of 
CSDH.
Methods and analysis This is a prospective, randomised, 
controlled, parallel group, non- inferiority multicentre trial 
comparing single burr- hole evacuation of CSDH with 
intraoperative irrigation and evacuation of CSDH without 
irrigation. In both groups, a passive subdural drain is 
used for 48 hours as a standard of treatment. The primary 
outcome is symptomatic CSDH recurrence requiring 
reoperation within 6 months. The predefined non- inferiority 
margin for the primary outcome is 7.5%. To achieve 
a 2.5% level of significance and 80% power, we will 
randomise 270 patients per group. Secondary outcomes 
include modified Rankin Scale, rate of mortality, duration 
of operation, length of hospital stay, adverse events and 
change in volume of CSDH.
Ethics and dissemination The study was approved 
by the institutional review board of the Helsinki and 
Uusimaa Hospital District (HUS/3035/2019 §238) and duly 
registered at  ClinicalTrials. gov. We will disseminate the 
findings of this study through peer- reviewed publications 
and conference presentations.
trial registration number NCT04203550
IntroduCtIon
Chronic subdural haematoma (CSDH) is the 
most common type of intracranial haemor-
rhage and one of the most common clinical 
diagnoses necessitating neurosurgical treat-
ment. CSDHs are typically caused by minor 
head trauma and consecutive tearing of 
bridging veins, leading to a haemorrhage in 
between the dura mater and the arachnoid 
membrane. The delay in the actual diag-
nosis of CSDH can be quite substantial due 
to the difficulty of the diagnosis in the early 
phase when neurological symptoms—such 
strengths and limitations of this study
 ► This is a multicentre nationwide prospective ran-
domised controlled trial, with a pragmatic trial de-
sign to increase generalisability.
 ► The study was designed in collaboration with patient 
organisation experts.
 ► The healthcare system in Finland facilitates the 
follow- up of patients (particularly with respect to our 
primary outcome, symptomatic chronic subdural 
haematoma (CSDH) requiring reoperation) as CSDH 
surgery is centralised to the five neurosurgical de-
partments participating in the trial.
 ► Although the surgeon performing the surgery obvi-
ously cannot be blinded to the group assignment, 
we have tried to maintain the masking of the treat-
ment allocation by not disclosing it in the healthcare 
records.
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as progressive headache, mental deterioration or confu-
sion, or deterioration of the patient's overall health—are 
quite unspecific. However, when the disease progresses 
and causes more direct compression to the underlying 
brain tissue, more specific progressive neurological signs 
ensue, including motor and sensory deficits, dysphasia 
and epileptic seizures, and the diagnosis becomes more 
evident. If left untreated, CSDH may also lead to loss 
of consciousness or even death. The definite diagnosis 
of CSDH is most commonly based on CT or MRI of the 
brain. On a CT scan, CSDH is usually of hypodense or 
isodense character and will feature a concavo- convex 
shape between the skull and the cortex.
For symptomatic CSDHs, the treatment is operative. 
The mainstay of treatment includes burr- hole cranios-
tomy and intraoperative intracranial irrigation, followed 
by subdural drainage.1 With current treatment strategies, 
the recurrence rate after CSDH treatment is approx-
imately 10%.2 Low risk of bias evidence exists on the 
role of subdural drain in recurrence rate reduction but 
the role of intraoperative irrigation is more controver-
sial. Our literature review revealed a total of 10 studies 
assessing the effect of intraoperative irrigation: only one 
study employed a randomised study protocol3 while the 
others were retrospective analyses. Sample sizes ranged 
from 56 to 186 patients, and the most commonly used 
outcome was the rate of haematoma recurrence. Of these 
10 studies, two studies found that intraoperative irriga-
tion was associated with a significantly lower recurrence 
rate in comparison to no intraoperative irrigation,4 5 six 
studies found no difference in recurrence rates between 
intraoperative and no intraoperative irrigation,3 6–10 
and two studies found that no intraoperative irrigation 
was associated with a significantly lower recurrence rate 
compared with irrigation.11 12
It is possible that intraoperative irrigation is an unnec-
essary prolongation of the surgical procedure, thereby 
increasing the risk for infections, rebleeding and the stress 
levels of patients undergoing the procedure under local 
anaesthesia. There is also evidence to suggests that irriga-
tion per se may be harmful. There are reports of increased 
risk of treatment- associated morbidity and complications 
such as postoperative pneumocephalus9 11 13 and also of 
direct irrigation- induced intracerebral and subarachnoid 
haemorrhage.14
We designed a pragmatic, parallel group, randomised, 
controlled multicentre non- inferiority trial to compare 
the use of intraoperative irrigation with no intraopera-
tive irrigation for the operation of symptomatic CSDH 
(by burr- hole craniostomy and subdural drainage for 
48 hours). We hypothesise that a treatment that involves 
no intraoperative irrigation results in non- inferior 
outcome compared with a treatment that involves intra-
operative irrigation. Non- inferiority of the new treatment 
(no irrigation) with respect to the gold- standard treat-
ment (irrigation) is of interest on the premise that the 
new treatment has some other advantages, such as shorter 
operative time and therefore reduced stress to patient, 
reduced cost, fewer adverse events (AEs) and technically 
more simple.15 We consider non- inferiority proven if the 
rate of recurrence in the no- irrigation group (N- IR) is 
within the predefined non- inferiority margin of the rate 
observed in the IR together with no significantly increased 
risk of harm.
MAtErIAls And AnAlysIs
overview of study design
Finnish study of intraoperative irrigation versus drain 
alone after evacuation of chronic subdural haematoma 
(FINISH) is a multicentre, prospective non- inferiority 
randomised controlled trial, with the primary objective 
to compare intraoperative irrigation to no irrigation in 
the treatment of CSDH by single burr- hole craniostomy 
and subdural drainage. Except for randomisation to irri-
gation versus no irrigation, the management of study 
participants will not differ. Eligible participants are block 
randomised in a 1:1 allocation rate to one of two arms: 
(1) intraoperative irrigation or (2) no intraoperative 
irrigation.
This protocol has been written according to the Stan-
dard Protocols Items: Recommendations for Inter-
ventional Trials (SPIRIT) guidelines for reporting a 
randomised controlled trial study protocol (the SPIRIT 
Figure and Checklist are available as online supplemen-
tary additional file 1).16 A summary of the trial is shown in 
online supplementary additional file 2.
study settings
Participating sites are the neurosurgical departments at 
Helsinki University Hospital (Helsinki, Finland), Kuopio 
University Hospital (Kuopio, Finland), Tampere Univer-
sity Hospital (Tampere, Finland), Turku University 
Hospital (Turku, Finland) and Oulu University Hospital 
(Oulu, Finland). All these five units are tertiary referral 
centres and the only units delivering neurosurgical care 
in Finland.
Participant selection and recruiting process
We will screen all patients who are referred for CSDH 
surgery to the aforementioned departments of neurosur-
gery for trial eligibility. A standard clinical examination 
and a brain CT or MRI examination will be performed. 
Patients with clinical and imaging findings consistent 
with a diagnosis of symptomatic CSDH and considered to 
benefit from operative treatment of CSDH by single burr- 
hole evacuation will be asked to participate in the trial.
Inclusion criteria
 ► Patients with a symptomatic unilateral or bilateral 
CSDH requiring burr- hole evacuation.
 – Predominantly hypodense or isodense on CT imag-
ing (or chronic hematoma on MRI).
 – Clinical symptoms correlating with the CSDH.
 – Patients with bilaterally operated CSDHs will be 
treated with the same protocol on both sides and 
analysed as a single study participant.
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Table 1 Table of events
Assessment Baseline Surgery 48–72 hours 6 weeks 6 months
Informed consent X
Randomisation   X
Demographics X
Antithrombotic medication X X X X
Neurological symptoms X X X X
Residence and mobility X X X
Imaging X X
Surgical details   X
Modified Rankin Scale X X X X
Survival status   X
Need for ipsilateral CSDH reoperation   X
Adverse events   X X X
CSDH, chronic subdural haematoma.
 ► Patients older than 18 years of age.
Exclusion criteria
 ► CSDH requiring surgical treatment other than burr- 
hole evacuation (eg, craniotomy).
 ► CSDH in a patient who has a cerebrospinal fluid 
shunt.
 ► Patients who have undergone any prior intracranial 
surgery.
 ► Comatose patients (Glasgow Coma Scale (GCS) score 
eight or lower) with absent motor responses to painful 
stimuli; decerebrate or decorticate posturing), where 
rapid haematoma evacuation is required.
 ► Patient’s postoperative cooperation is suspected to be 
insufficient for drain usage (ie, disoriented or semi-
conscious patient).
 ► Patient who has received active treatment for a haema-
togenic malignancy within the previous 5 years.
 ► Patient with a central nervous system malignancy or 
tumour that may cause the patient’s current symptoms 
or may interfere with the operation. For example, a 
small incidental meningioma without associated brain 
oedema, not in the vicinity of the planned burr hole, 
is not an exclusion criterion.
 ► Patient has an acute infection that requires antibiotic 
treatment.
 ► Patient has a high risk of life- threatening thrombosis 
(eg, recent coronary stent, intracranial stent, recent 
pulmonary embolism, low pressure cardiac valve 
replacement (mitral or tricuspid valve replacement)) 
and discontinuation of antithrombotic medication is 
not recommended.
Informed consent
At the first appointment in the emergency department or 
the neurosurgical ward, the attending neurosurgeon will 
provide the patients with detailed written and oral infor-
mation on the trial and ask patients to sign an informed 
consent form. Withdrawal from the study is possible at 
any time, without affecting the course of conventional 
treatment, in accordance with the latest version of the 
Declaration of Helsinki 2013.17
Due to the nature and emergency aspects of the disease 
(mass effect on the brain causing confusion and disori-
entation, lowered level of consciousness requiring urgent 
surgery), some patients will not be able to give written 
consent prior to randomisation. If the patient is unable to 
give written consent prior to the randomisation, delayed 
consent will be sought. In these cases, oral consent will be 
obtained from the next of kin after providing information 
regarding the trial. Following oral consent from the next 
of kin, the patient can be randomised. Following rando-
misation and surgery, written consent will primarily be 
obtained from the patient. However, in case of the patient 
being unable to give written consent due to neurological 
disability, written consent is obtained from the next of 
kin. In these cases, the next of kin has the right to with-
draw the patient’s consent at any time. Patients who are 
eligible for the trial but are not willing to undergo rando-
misation will be asked to be included in a simultaneous, 
pragmatic follow- up cohort.
Participants will be asked to sign the local Biobank 
agreements in order to collect and store subdural fluid 
samples and two venous blood samples (2×10 mL).
Collected data
We will document data in the electronic case report 
form (eCRF) preoperatively, intraoperatively and within 
48–72 hours postoperatively, as well as at 6 weeks (±2 
weeks) and at 6 months (see table 1 for table of events). 
All patients’ preoperative and postoperative head CT 
or MR images will be sent to the Picture Archiving and 
Communication System of the methods centre (Helsinki 
University Hospital) for analysis. Ten per cent of all images 
will be double read by independent assessors blinded to 
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other patient information. To preserve confidentiality, all 
participants are allocated a unique study identifier during 
the recruitment process, which is used on all data collec-
tion forms. All study documentation is held in secure 
offices, and the study researchers operate according to a 
signed code of confidentiality. All data are entered into a 
password- secured database by the data managers.
surgical technique
Current management of CSDHs at all participating 
centres includes single burr- hole evacuation with 
intraoperative irrigation followed by passive subdural 
drainage. As a routine, all burr- hole craniostomies are 
performed under local anaesthesia, often combined 
with intravenous sedation with benzodiazepines and/
or opioids during the operation. General anaesthesia 
is only used if the neurosurgeon or the anaesthesiolo-
gist considers it unsafe to perform the procedure under 
local anaesthesia. Routine preoperative antibiotic is 
given according to local protocols (normally a second- 
generation cephalosporin 30–60 min prior to incision). 
Typically, the surgeon drills one 14 mm burr hole over 
the maximum convexity of the CSDH. In case of bilat-
eral CSDHs, the surgeon performs the same procedure 
on both sides. If irrigation is used, after opening the 
dura, the surgeon irrigates the subdural collection 
with warm (body temperature) Ringer’s lactate saline 
until rinsing appears clear or at least 200 mL (in case 
of bilateral CSHD, 200 mL per side, ie, 400 mL total). 
After that, the surgeon will insert the subdural drain 
3–5 cm deep and parallel to skull. The position of the 
drain (anterior, posterior) is left to the discretion of 
the physician. Burr hole covers or haemostatics are not 
routinely used (eg, Spongostan, Tachosil). The type of 
subdural drain is not standardised, but all study centres 
use 10F drains. Following drain insertion, the distal end 
is tunnelled approximately 4–5 cm from the incision 
and connected to a passive ventricular drainage bag 
(through a non- return valve) and the skin incision is 
closed in two layers (normally absorbable 3–0 suture for 
subcutis/galea and non- absorbable 4–0 suture for skin). 
The drain is fixed to the skin in a secure way. The drain- 
to- skin fixation technique is left to the discretion of the 
operating surgeon. The drainage bag is positioned at 
bed level. The duration of subdural drainage is 48 hours 
(±12 hours).18 19 Patient mobilisation is allowed during 
drainage (drain is kept open). Prophylactic antibiotics 
during drainage are not routinely used.
randomisation
Patients will be randomised in a 1:1 allocation ratio strat-
ified only by study centre. We will use a random block 
randomisation technique, with a random block size of 
4, 6 or 8. A member of the FINISH study group will 
carry out randomisation when the patient is at the OR 
at the beginning of the operation. The randomisation 
will occur just prior to skin incision. The randomisation 
is a built- in property in the online eCRF system used in 
the trial (provided by Granitics, Espoo, Finland).
Intervention
Irrigation group
A burr- hole craniostomy is performed as described 
earlier. The dura is opened sharply and 10 mL of subdural 
exudate is aspired with blunt aspiration needle for a 
CSDH sample to be stored at −75℃ to be used for later 
analysis. Subdural space is irrigated by repeated rinsing 
with body temperature saline solution with a syringe and 
blunt needle until surgeon considers exudate to be clear. 
Minimum volume of irrigation will be 200 mL per oper-
ated side. The subdural drain is inserted 3–5 cm under-
neath the skull and parallel to it. Thereafter, operation is 
completed as described earlier. The total volume of irri-
gation as well as the duration of operation is recorded.
No-irrigation group
A burr- hole craniostomy is performed as described 
earlier. A small incision in the dura is made and 10 mL 
of subdural exudate is aspired with a blunt aspiration 
needle for a CSDH sample to be stored at −75℃ to be 
used for later analysis. The subdural drain is inserted 
approximately 3–5 cm underneath the skull and parallel 
to it. Thereafter, the operation is completed as described 
earlier. The duration of the operation is recorded.
blinding
Due to the nature of the treatment, it is not possible to 
blind the surgeon and OR staff from the treatment allo-
cation. Measures to minimise bias include:
 ► The randomisation is timed as closely as possible to 
the time of surgery (just prior to skin incision).
 ► The patient will not be informed of treatment 
allocation.
 ► Treatment allocation will not be documented in 
medical records (ie, all personnel participating in 
patient care after the operation will be blinded to 
allocation).
 ► The study group members collecting postoperative 
data, outcome data, imaging data and performing the 
statistical analyses will be blinded to treatment arm 
over the entire course of the trial, until the data anal-
yses are carried out.
 ► The primary and secondary outcome measures are 
all evaluated in blinded matter, that is, the outcome 
assessor will be blinded with regard to treatment 
allocation
Emergency unblinding will occur only in exceptional 
circumstances when requested by the patient’s clin-
ical team (eg, need to treat a serious AE (SAE)), when 
knowledge of the actual treatment is essential for further 
management of the patient.
Compliance to treatment allocation and possible crossover
The per- protocol (PP) treatment is 0 mL of intracranial 
irrigation in the N- IR group and ≥200 mL (per operated 
side) of intracranial irrigation in the IR group. In the 
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event of protocol breach, crossovers will be handled as 
follows:
 ► If the patient is randomised to the IR group and the 
intracranial irrigation volume is between 1 mL and 
200 mL, the patient is not considered a crossover.
 ► If the patient is randomised to the IR group and the 
intracranial irrigation volume is 0 mL, the patient is 
considered a crossover (belongs to the N- IR group).
 ► If the patient is randomised to the N- IR group and 
1–199 mL of intracranial irrigation is used, the patient 
is not considered a crossover.
 ► If the patient is randomised to the N- IR group 
and ≥200 mL of intracranial irrigation is used, the 
patient is considered a crossover (belongs to the IR 
group).
 ► In case of intervention failure (eg, not being able to 
insert subdural drain, intended or unintended drain 
removal before 36 hours), the patient is not consid-
ered a crossover.
Primary outcome measure
Our primary outcome measure is the rate of reoperations 
of ipsilateral CSDHs within 6 months.
Indication for reoperation and reoperation technique
The decision to proceed to reoperation is made by the 
treating neurosurgeon and will be made by the same indi-
cations as the primary operation (ie, symptom recurrence 
or insufficient resolution of clinical symptoms correlating 
to imaging findings (CT or MR imaging) of CSDH). All 
reoperations will be conducted according to the current 
standard (ie, burr- hole with irrigation and subdural 
drain placement). In case of recurrence requiring reop-
eration, unblinding will not occur automatically, only in 
cases when the neurosurgery team treating the patient 
considers this information necessary for optimal care of 
the patient.
secondary outcome measures
The study is not powered for secondary outcome measure 
comparisons and these outcomes (analyses) will be consid-
ered exploratory. The secondary outcomes include:
1. Modified Rankin Scale at 6 months after operation.
2. Mortality within 6 months of operation.
3. Duration of the operation.
4. Hospital length of stay (index hospital and need for 
further care).
5. CSDH volume reduction at 2 months after operation.
safety endpoints
Safety endpoints within 6 months of operation, including 
the number and severity of AEs and procedure- related 
AEs (PRAE). AEs are categorised as SAEs and minor AEs 
(MAE). Procedure- related (severe and minor) AEs will be 
reported separately.
SAEs are defined as any inappropriate medical occurrence 
or effect that results in death, is life- threatening, requires 
hospitalisation or prolongation of an existing inpa-
tient hospitalisation, results in persistent or significant 
disability or incapacity, or is another important medical 
event.
 ► Life- threatening in the definition of SAE refers to 
an event when the patient was at risk of death at the 
time of the event and does not refer to an event where 
the event might have hypothetically caused death. 
Prolonged hospitalisation due to delayed transfer will 
not be considered an AE or SAE.
Examples of SAEs are death, acute myocardial infarc-
tion, pulmonary embolism, systemic infection, acute 
cerebral infarction (PRAE), intracranial infection 
(PRAE), epileptic seizures (PRAE) and acute postop-
erative intracranial haematoma (PRAE).
MAEs are defined as clinically mild manifestations, 
referent to that the patient might be aware of the event 
or symptom but the event or symptom is easily tolerated 
by the patient.
 ► Examples of MAEs are local wound infection manage-
able with oral antibiotics (PRAE), abnormal skin 
bleeding from the wound (PRAE), other local infec-
tion manageable with oral antibiotics and deep venous 
thrombosis not causing pulmonary embolism.
Follow-up
The follow- up period is 6 months. We will arrange a clin-
ical outpatient follow- up visit for all patients at 4–8 weeks 
postoperatively (6 weeks±2 weeks). Before that, a post-
operative brain CT will be performed. If the patient was 
preoperatively using any form of antithrombotic medi-
cation, the medication is not routinely restarted without 
reasonable clinical indication before the control brain 
CT. All recurrences requiring surgery within 6 months 
and complications within 6 months will be recorded. At 
6 months, functional outcome (modified Rankin Scale 
(mRS)) will be assessed by a FINISH study group member 
by phone interview. Further, for each patient, mortality 
will be verified through the Finnish Official Cause- of- 
Death Statistics at 6 months. This statutory register is 
virtually 100% complete because each death, its associ-
ated official death- certificate, and the corresponding 
person information in the Finnish computerised popula-
tion register are cross- checked.
sample size
The trial is designed to ascertain whether drain without 
irrigation is non- inferior to drain with irrigation, with 
the rate of reoperations of ipsilateral CSDHs within 6 
months as the primary outcome. We based the standard 
rate of reoperations (9.6%) on the results from a recent 
Cochrane review that reported the recurrence rates after 
CSDH evacuation followed by subdural drainage in six 
randomised controlled trials (RCTs) with more than 30 
patients per treatment arm.2 This yielded a maximum 
allowed margin of 9.0% to achieve non- inferiority. 
Following a consensus meeting with the trial investigators, 
the non- inferiority margin was lowered to 7.5%. Thus, 
with a non- inferiority margin of 7.5%, a 2.5% level of 
statistical significance (alpha=0.025) and an 80% power 
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(beta=0.20), we will need 243 patients per study group.20 
Accounting for a drop- out rate of 10%, required group 
size increases to 270 per study group. Accordingly, we set 
the recruitment target at 540 patients.
data management
All study data will be stored in an eCRF provided by 
Granitics (Espoo, Finland). Data are entered locally by the 
local research team. On receipt of the data, the FINISH 
personnel, blinded to the group allocation, will make a 
visual check of the data and query all missing, implausible 
and inconsistent data. Hospital patient records will also 
be used to collect missing data and to interpret incon-
sistent or implausible data. Participant files will be main-
tained in storage (both in electronic and paper format) 
at the coordinating centre for a period of 15 years after 
completion of the study.
data sharing
Data generated by our study will be made available as soon 
as possible and will be available on reasonable request. 
Data access requests will be reviewed by the FINISH 
steering group. Requestors will be required to sign a data 
access agreement. Only anonymised data will be shared.
statistical analysis
The statistical analysis will be performed both according 
to intention- to- treat (ITT) and PP principles. We will 
claim non- inferiority of single burr- hole evacuation 
without irrigation and subdural drainage only if this 
outcome is supported both by the ITT and the PP anal-
ysis. The ITT analysis will be performed using the full 
analysis set (FAS), defined as all randomised patients in 
the groups allocated to by the randomisation. No exclu-
sions other than caused by missing information will be 
made. No imputation will take place. The PP analysis will 
be performed on the subset of the FAS that is compliant 
with the protocol, have a completed treatment, available 
measurements and no major protocol violations nor entry 
criteria violations.
Summary statistics will be presented for both groups. 
Continuous variables will be presented in terms of mean 
values or medians with SDs and IQRs, respectively. Cate-
gorical variables will be presented with relative frequen-
cies in percent.
The results from the statistical analysis will be consid-
ered to support a claim of non- inferiority if the upper 
limit of a one- sided 97.5% CI (or equivalently a 95% two- 
sided CI) excludes a difference in the primary endpoint 
in favour of the IR of more than 7.5%. The centre strati-
fication of the randomisation will be accounted for in the 
calculation of the CI.
Exploratory analyses of secondary and other binary 
endpoints will be performed using the X2 test or logistic 
regression analysis. Continuous outcomes will be anal-
ysed using Student’s t- test or analysis of covariance. Poten-
tial effect modifiers (patient age, unilateral vs bilateral 
CSDH, use of antithrombotic medication, preoperative 
mRS and preoperative clinical status, haematoma density, 
haematoma size and presence of membranes on preop-
erative imaging) will be analysed by including interaction 
terms in statistical models.
The primary endpoint will be investigated as described 
above using a CI, which is equivalent to using a non- 
inferiority test with a one- sided p value of 0.025 (or a two 
sided of 0.05). The statistical testing of other endpoints 
will also be performed using a two- sided significance level 
of 0.05. The statistical analysis will be performed using 
appropriate statistical software packages.
Prior to the statistical analysis, a statistical analysis plan 
will be finalised and an independent statistician will 
approve a dataset with sufficient data quality for the statis-
tical analysis. Another statistician blinded to treatment 
arm will perform the analyses.
Blinded data interpretation
As in previous studies,21 22 we will interpret the results 
of the trial according to a blinded data interpreta-
tion scheme.23 In brief, an independent statistician will 
provide the Writing Committee of the FINISH trial with 
blinded results from the analyses with the groups labelled 
group A and group B. The Writing Committee will then 
contemplate the interpretation of the results until a 
consensus is reached and all alternative interpretations of 
the findings are agreed on in writing. Once a consensus 
is reached, we will record the minutes of this meeting in 
a document coined ‘statement of interpretation’, which 
will be signed by all members of the Writing Committee. 
Only after reaching this common agreement will the data 
manager and independent statistician break the rando-
misation code and the correct interpretation chosen. A 
manuscript will then be prepared and finalised for the 
publication of the results. Detailed minutes of blinded 
data interpretation meetings will be provided as a supple-
ment to the trial manuscript.
Patient and public involvement
To achieve a more patient- friendly design for our trial, 
we recruited five patient experts from the European 
Patients’ Academy on Therapeutic Innovation (EUPATI 
Finland, https:// fi. eupati. eu/) while designing the study. 
They were asked to review the informed consent form 
and questionnaires of the study. Further, these experts 
were asked to assess the burden of the intervention, 
time required to participate in the study, and outcomes 
all of which they estimated to be reasonable. After the 
FINISH study is completed, we will deliberate together 
with EUPATI Finland on how to share the study results 
with the general public.
data safety and monitoring committee
Study monitoring is provided by the Clinical Research 
Institute of Helsinki University Hospital, who will ensure 
the quality of data collection and trial integrity. The 
monitoring is performed in accordance with currently 
valid rules and regulations, Good Clinical Practice and 
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the standardised instructions of the Clinical Research 
Institute Helsinki University Hospital.
The members of the data safety and monitoring 
committee (DSMC) are neurosurgeons independent of 
the trial and have neither financial nor scientific conflicts 
of interest with the trial. The DSMC will oversee the 
interim analyses. The purpose of the interim analysis is 
safety surveillance. The interim analyses are performed 
after 50, 100 and 200 patients. No efficacy- related early 
stopping is planned.
Ethics and dissemination
The study was approved by the institutional review board 
(IRB) of the Helsinki and Uusimaa Hospital District on 
13 November 2019 (HUS/3035/2019 §238, updated 26 
February 2020).
All participating centres will obtain local institutional 
research approvals for the consent form template, the 
eCRF and any additional protocol amendments. Any 
protocol amendment will be communicated to the site 
investigators, the IRB, trial participants and trial registries 
as necessary.
Information about the study participants will be kept 
confidential and will be managed in accordance with the 
following rules: (1) all study- related information is stored 
securely at the clinical sites, (2) all possible study partic-
ipant information in paper form is stored in locked file 
cabinets and is accessible only to study personnel, (3) all 
CRFs are identified only by a coded patient number, (4) 
all records that contain patient names or other identifying 
information are stored separately from the study records 
that are identified only by the coded patient number and 
(5) all local databases are password protected.
The results of the study will be published in an inter-
national journal and presented at (inter)national 
congresses. Trial results will be disseminated to the public 
in collaboration with EUPATI Finland.
dIsCussIon
To the best of our knowledge, this is the first large scale 
multicentre RCT comparing intraoperative irrigation 
with no intraoperative irrigation after burr- hole cranios-
tomy and subdural drain placement for CSDH. The 
incidence of CSDH in Finland is approximately 18/100 
000, reaching as high as 130/100 000 in persons over 80 
years old.24 As a consequence of the ageing population, 
more frequent use of antithrombotic medication and 
the improved access to diagnostics in most high- income 
countries, the incidence of CSDH is expected to increase 
in the future.25 The risk of complications following CSDH 
is rather low, but reducing the risk of recurrence is essen-
tial to avoid over- hospitalisation of otherwise fragile 
patients, which could be detrimental.26 Current studies 
examining strategies to decrease risk of recurrence 
include the Swedish study of irrigation- fluid temperature 
in the evacuation of CSDH (SIC!),27 the Dutch dexa-
methasone therapy versus surgery for CSDH (DECSA 
trial),28 the British dexamethasone for adult patients with 
a symptomatic CSDH trial,29 and two Canadian studies 
looking at the role of tranexamic acid in the treatment of 
CSDHs (TRACS trial, NCT0256812430 and TRACE trial, 
NCT03280212).
A multicentre RCT that could show a decrease in recur-
rence rates has the potential to set a new gold standard 
of therapy, which would influence the treatment of these 
patients all over the world. If subdural irrigation fails to 
show any benefit over no irrigation, it would translate to a 
reduction in the risk of iatrogenic surgical complications 
and shortened operation times. It may also enable oppor-
tunities to develop newer, minimally invasive surgical 
techniques, including only subdural drain placement. 
This would not only benefit the individual patient but 
also healthcare systems all over the world, considering the 
sharply increasing incidence of CSDH.
A major strength of the study is that the five partici-
pating centres cover 100% of the Finnish population in 
terms of provision of neurosurgical care. In Finland, the 
surgical treatment of CSDH is exclusively carried out in 
University Hospital clinics, meaning that the follow- up 
regarding the primary endpoint (recurrence) should be 
100%. Also, in a highly digitalised healthcare system (local 
electronic healthcare databases since the early 2000s and 
nationwide electronic healthcare database since 2010) 
where every citizen has a unique personal identification 
number, the chances for successful follow- up regarding 
other endpoints is extremely high. A limitation is that it 
is impossible to blind the treating surgeon in relation to 
the treatment arm (irrigation or no irrigation). Further-
more, we cannot adjust for subtle differences in surgical 
technique between surgeons, although all participating 
centres as a whole perform the surgeries similarly. For 
example, the normal surgical technique involves irriga-
tion until the fluid is deemed to be clear. However, in 
order to ensure a sufficient amount irrigation, we set a 
minimum threshold of 200 mL (per side).
trIAl stAtus
The trial started recruiting patients in January 2020 in 
Helsinki and the other centres will start recruiting during 
the spring of 2020.
study administration structure
Writing Committee: Pihla Tommiska, Rahul Raj, Chris-
toph Schwartz, Teemu Luostarinen, Jarno Satopää, Simo 
Taimela, Teppo Järvinen, Jussi Posti, Teemu Luoto, Ville 
Leinonen, Sami Tetri, Timo Koivisto and Kimmo Lönnrot.
Steering Committee: Kimmo Lönnrot (chair), Riku 
Kivisaari (cochair), Teemu Luostarinen (cochair), Rahul 
Raj, Jussi Posti, Teemu Luoto, Ville Leinonen, Sami Tetri 
and Timo Koivisto.
Methods Centre: Helsinki University Hospital: Rahul 
Raj (principal investigator), Jarno Satopää (coprincipal 
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investigator), Pihla Tommiska (coprincipal investi-
gator, data management), Maarit Tuomisto (research 
coordinator).
Central Adjudication Committee: Kimmo Lönnrot, 
Riku Kivisaari, Teemu Luostarinen, Rahul Raj, Jussi Posti, 
Teemu Luoto, Ville Leinonen, Sami Tetri and Timo 
Koivisto.
Data Safety Monitoring Board: Martin Lehecka (MD, 
PhD, A. Prof, Helsinki University Hospital, Finland), 
Frederick A. Zeiler (MD, PhD, A. Prof, Rady Faculty of 
Health Sciences, University of Manitoba, Canada), Jiri 
Bartek Jr. (MD, Karolinska University Hospital, Stock-
holm, Sweden).
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